The second federal bellwether trial over transvaginal mesh devices has settled for an undisclosed sum, while manufacturer C.R. Bard Inc. continues to press that the FDA’s approval of its device should be admitted as evidence to jurors.
The settlement was revealed in a filing on Friday by U.S. District Judge Joseph Goodwin, who is overseeing litigation over transvaginal mesh products in Charleston, W.Va. A separate federal jury in the first bellwether trial awarded $2 million to a woman who alleged that Bard failed to warn of defects in its product that caused her bleeding and pain.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
